Max Robotics — Global Service Robot Directory + US Certification

About

Vincenzo Serretta is a distinguished urologist whose research has shaped the understanding and management of urological cancers, particularly bladder and prostate malignancies. His major contributions include pioneering work on the role of chemoresistance and molecular markers in bladder cancer prognosis, as well as advancing surgical techniques for organ-sparing treatments. With over 200 publications and a citation count exceeding 5,000, his work has had a lasting impact on clinical practice. Notably, Serretta led the first Italian multicenter trial on adjuvant chemotherapy for high-risk bladder cancer, a study that influenced international guidelines. He has also been a key figure in the European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Group, contributing to landmark trials. Beyond his clinical research, Serretta has been an advocate for medical education, as seen in his reflective paper on how the COVID-19 pandemic could catalyze positive changes in urology residency training. His career exemplifies a blend of rigorous science, clinical innovation, and a commitment to mentoring the next generation of urologists.